<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708595/" ref="ordinalpos=114&amp;ncbi_uid=5499198&amp;link_uid=PMC3708595" image-link="/pmc/articles/PMC3708595/figure/F4/" class="imagepopup">Figure 4. Diversity and frequency of ACC genetic changes culminating in aberrant <span class="highlight" style="background-color:">signaling</span> pathways.  From: The Mutational Landscape of Adenoid Cystic Carcinoma. </a></div><br /><div class="p4l_captionBody">Alterations are defined by somatic mutations, homozygous deletions, high-level focal amplifications, and structural variants validated by FISH or PCR. Frequencies are expressed as a percentage of all cases. Red background denotes activating alteration, blue background denotes inactivating alteration, white background denotes numerous alterations, and purple background denotes alteration of unclear significance. Interactions based upon IPA or Pathway Commons.38 (<b>a</b>). Epigenetic modification. (<b>b</b>). DNA damage/checkpoint signaling pathway. (<b>c</b>). MYB/MYC signaling pathway, with fusion denoted by recurrent t(6;9) translocation between MYB and NFIB. (<b>d</b>). FGF/IGF/PI3K signaling pathway. (<b>e</b>). Notch signaling pathway.</div></div>